Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New cell therapy targets tough cancers in early trial

NCT ID NCT07014878

First seen May 20, 2026 · Last updated May 24, 2026 · Updated 1 time

Summary

This early-phase study tests DCTY1102, a personalized cell therapy, in 18 adults with advanced colorectal, lung, or pancreatic cancers that have a specific KRAS/NRAS G12D mutation and HLA type. Participants receive a single infusion of their own genetically modified immune cells after a short chemotherapy course. The main goals are to check safety and find the best dose, with a secondary look at whether the treatment shrinks tumors.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Fudan University Shanghai Cancer Center

    Shanghai, Shanghai Municipality, 200032, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Jiangsu Province Hospital

    Shanghai, Shanghai Municipality, 210029, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.